Background The consensus molecular subtypes (CMSs) of colorectal cancer (CRC) capture
tumor heterogeneity at the gene-expression level. Currently, a restricted number of …

Colorectal cancer (CRC) is one of the most prevalent cancers, with more than one million
new cases every year. In the last few decades, several advancements in therapeutic and …

Background It is generally accepted that colorectal cancer (CRC) originates from cancer
stem cells (CSCs), which are responsible for CRC progression, metastasis and therapy …

Colon cancer inter-tumour heterogeneity is installed on multiple levels, ranging from (epi)
genetic driver events to signalling pathway rewiring reflected by differential gene expression …

Objectives Transcriptomic-based subtyping, consensus molecular subtyping (CMS) and
colorectal cancer intrinsic subtyping (CRIS) identify a patient subpopulation with …

Purpose: BRAF mutations are grouped in activating RAS-independent signaling as
monomers (class 1–V600E) or as dimers (class 2–codons 597/601), and RAS-dependent …

Background A considerable number of patients with stage II/III colorectal cancer (CRC) will
relapse within 5 years after surgery, which is a leading cause of death in early-stage CRC …

Abstract Purpose of Review This review seeks to provide an informed prospective on the
advances in molecular profiling and analysis of colorectal cancer (CRC). The goal is to …

The classification of colorectal cancer (CRC) plays a pivotal role in predicting a patient's
prognosis and determining treatment strategies. The consensus molecular subtype (CMS) …

Background Tumour budding and poorly differentiated clusters (PDC) represent forms of
tumour invasion. We hypothesised that T-cell densities (reflecting adaptive anti-tumour …